Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-MI: Intracoronary Tenecteplase in STEMI
NCT03998319Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing Tenecteplase with Placebo (2 arms). Primary endpoints: Cardiovascular mortality and rehospitalisation for heart failure at 24 months, MI size as a % of LV mass at 6 months and 1 more. Started Oct 2021; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03998319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998319.